Transformational Research Awards
Apply for a Transformational Research Award and transform the lives of people with blood cancer. Because the time to beat blood cancer is now.
To be notified when the spring call opens, please contact us at [email protected]
Introduction
Through this scheme, we aim to support ambitious research that aims to make substantial progress towards a transformational change for people with any type of blood cancer or a precursor condition, from any age group (including children and young people).
Transformational Research Awards support advanced/late-stage pre-clinical research, clinical and experimental medicine (including clinical studies or trials), and research to accelerate the uptake of new treatments and other interventions into the NHS.
Application process
This is a two-stage scheme where all applicants are asked to first submit an Expression Of Interest (EOI). These EOIs are reviewed and shortlisted by the assembled committee for this scheme. Shortlisted EOI applicants are then invited to submit a full application.
Key dates 2025-2026 & 2026-2027
Applicants to the 2025- 2026 scheme will be notified of outcomes in January 2026.
EOIs for the 2026-2027 scheme are expected to open in Spring 2026. When the scheme opens this page will be updated with the EOI guidance and further information on how to submit your EOI.
Grant amount
Grants will typically be awarded for up to five years and for a maximum of £1m.
The scheme's impact
Our Transformational Research Award scheme was introduced in 2024 and represented a reintroduction of funding from Blood Cancer UK for late stage translational and clinical research.
The first awards were made in January 2025 and this research has the potential to transform the lives of people affected by blood cancer
-
5 Grants awarded last year
-
£4.9 million Total invested
-
23% Applicant success rate
Our research
Our £500 million investment in research since 1960 has helped transform treatments and taken us to the point where beating blood cancer is now in sight. Our researchers are working to finish the job.
More About ThisPreviously awarded TRAs
- Finding a new and better way to treat acute promyelocytic leukaemia (APL)
- Advancing CAR-T cell therapy to transform treatment and provide hope for people with myeloma
- Revolutionising stem cell transplants to treat acute myeloid leukaemia (AML)
- Using NHS Data to Improve treatment for people with myeloma
- A new combination of drugs to treat Primary Central Nervous System Lymphoma (PCNSL)